Stress, Obesity, Liver fat, Insulin resistance in Depressio
- Conditions
- F32F33Depressive episodeRecurrent depressive disorder
- Registration Number
- DRKS00004324
- Lead Sponsor
- Zentralinstitut für Seelische Gesundheit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 58
Inclusion Criteria
Patients: depressive episode (unipolar), severity: HDRS >= 18
Exclusion Criteria
Patients and controls:
not competent for consent, insufficient german language, diabetes, dyslipidemia, contraindication for MRI
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method This is a non-interventional trial. The above-mentioned dependent variables will be compared between healthy controls and depressed patients as well as between subgroups of depressed patients (e.g. high vs. low activity of the HPA system): functional imaging of the brain (MRI), breast and abdominal imaging (MRI), blood analysis for metabolic and genetic parameters, dexamethasone suppression test, cortisol in saliva and urine. This is a cross-sectional trial.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways connect chronic stress to hepatic steatosis in DRKS00004324 depression cohort?
How does insulin resistance in F33 patients correlate with antidepressant efficacy in DRKS00004324?
Which inflammatory biomarkers (e.g., CRP, adipokines) predict metabolic complications in DRKS00004324 participants?
What are the long-term metabolic adverse events in depression patients with obesity from DRKS00004324 observations?
How do lifestyle interventions targeting HPA axis dysregulation compare to SSRIs in managing depression-related insulin resistance?